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Abstract
Background: The polo-like kinases (Plks) are a group of serine/threonine kinases which have roles
in many aspects of cellular function including the regulation of mitotic activity and cellular stress
responses. This study focuses on Plk4, the most divergent member of the Plk family, which is
necessary for proper cellular proliferation. More specifically, alterations in Plk4 levels cause
significantly adverse mitotic defects including abnormal centrosome duplication and aberrant
mitotic spindle formation. We sought to clarify the effect of reduced Plk4 levels on the cell by
examining transcript profiles of Plk4 wild-type and heterozygous mouse embryonic fibroblasts
(MEFs). Subsequently, the levels of several key proteins involved in the DNA damage response
were examined.
Results: 143 genes were found to be significantly up-regulated in the heterozygous MEFs
compared to their wild-type counterparts, while conversely, 9 genes were down-regulated.
Numerous genes with increased transcript levels in heterozygous MEFs were identified to be
involved in p53-dependent pathways. Furthermore, examination of the promoter regions of all up-
and down-regulated genes revealed that the majority contained putative p53 responsive elements.
An analysis of transcript levels in MEFs after exposure to either ionizing or ultraviolet radiation
revealed a significant change between wild type and heterozygous MEFS for Plk4 transcript levels
upon only UV exposure. Furthermore, changes in protein levels of several important cell check-
point and apoptosis regulators were examined, including p53, Chk1, Chk2, Cdc25C and p21. In
heterozygous MEFs, p53, p21 and Chk2 protein levels were at significantly higher levels.
Furthermore, p53 activity was increased 5 fold in the Plk4 heterozygous MEFs.
Conclusion: Global transcript profiles and levels of key proteins involved in cellular proliferation
and DNA damage pathways were examined in wild-type and Plk4 heterozygous MEFs. It was
determined that Plk4 haploinsufficiency leads to changes in the levels of RNA accumulation for a
number of key cellular genes as well as changes in protein levels for several important cell cycle/
DNA damage proteins. We propose a model in which reduced Plk4 levels invoke an increase in
p53 levels that leads to the aforementioned changes in global transcription profiles.
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Background
Plk4 (Sak), is a member of the polo-like kinase (Plk) fam-
ily of serine/threonine kinases which are involved in the
regulation of the cell cycle, cellular response to stress such
as DNA damage, and the duplication and maturation of
centrosomes [1-4]. Deregulation of the Plks by overex-
pression, depletion via epigenetic silencing or loss of het-
erozygosity (LOH) has implicated them in the
development of centrosome abnormalities and has been
associated with a CIN (chromosomal instability) pheno-
type and malignancy. Plk4 is a major regulator of centriole
duplication as indicated first by an increase in the number
of supernumerary centrosomes correlated with Plk4 over-
expression, and second, by a reduction in centriole dupli-
cation with the eventual development of mono-polar
spindles upon repeated cell divisions observed after RNA
interference for Plk4 [5-8]. Homozygous null Plk4 mice
are embryonic lethal at ~E7.5 of development, with an
increase in the proportion of mitotic cells, whereas Plk4
heterozygous mice are phenotypically normal [9]. Inter-
estingly aged Plk4 heterozygous mice display haploinsuf-
ficiency with tumours developing at a high frequency in
major sites such as the liver and lung [10]. Haploinsuffi-
ciency for Plk4 affects normal progression through the cell
cycle and maintenance of the genome. For example, in a
two thirds liver hepatectomy model, Plk4 heterozygous
hepatocytes had an increased rate of tri- and tetra-polar
spindle complexes with frequent mitotic errors as com-
pared to those form wild-type regenerating livers [10]. At
9–12 months post-hepatectomy all the Plk4 heterozygous
mice had abnormal liver morphology and there was an
increased rate of tumourigenesis [10]. These results sug-
gest that Plk4 haploinsufficiency potentially leads to
increased aneuploidy a likely tumour promoting event.
Plk4 loss also has implications in human malignancy,
where LOH for Plk4 was found in the majority of a small
sample of hepatocellular carcinomas [10].
Plks 1–3 in general all play important roles in the regula-
tion of the cell cycle and the DNA damage response. Fur-
thermore, several of their respective substrates are in
common, with the individual Plks likely placing their sub-
strate under tighter or opposing control. For example,
both Plk3 and Plk1 phosphorylate Cdc25C and p53 by
targeting different residues in each case. Plk3 phosphor-
ylates Cdc25C on serine 216 [11], a site that is also tar-
geted by Chk1 and Chk2 [4,12]. Phosphorylation of
serine 216 of Cdc25C is inhibitory, which is due to
sequestration of the protein phosphatase in the cytoplasm
by 14-3-3 protein, thus blocking mitotic entry [13].
Human Cdc25C is phosphorylated on Ser-198 by Plk1,
part of an activation amplification loop that increases the
phosphatases activity to allow mitotic entry [14]. Polo-
like kinase 1 (Plk1) is known to inhibit p53 function by
physical interaction [15], while phosphorylation of p53 at
Ser 20 by Plk3 serves to functionally link DNA damage
with increased p53 activity [16]. Chk2 is another protein
that is phosphorylated by the Plks. Plk1 interacts with,
phosphorylates and colocalizes with Chk1 [17], Plk3
phosphorylates Chk2 at two residues, which results in
subsequent phosphorylation of Chk2 on T68 by ATM in
response to DNA damage, thus upregulating Chk2 activity
[18,19].
Similar to the other Plk family members, which have
established roles in DNA damage pathways, Plk4 likely
functions within or is a target of DNA damage pathways.
This is supported by the observation that Plk4 interacts
with and phosphorylates p53 [10,20]. Plk4 expression is
repressed in a p53 dependent manner in response to DNA
damaging agents, with the p53 repression of Plk4 activity
occurring through the recruitment of a histone deacetylase
(HDAC) transcription repressor [21]. Additionally,
Cdc25C, a key regulator of the entrance into mitosis and
target of DNA damage proteins, is a substrate for Plk4
[22]. Significant phenotypic differences are also observed
between Plk4 wild-type and heterozygous mouse embry-
onic fibroblasts (MEFs) [10]. Contrary to what would be
expected, heterozygous Plk4 MEFs display a phenotype
typified by multiple centrosomes which lead to multipo-
lar spindles, mitotic failure and delayed proliferation [10].
All the evidence published to date is consistent with a
model as suggested by Habendanck et al (2005) in which
reduced Plk4 activity causes occasional cellular division
failure as a result of aberrant centrosome duplication and
subsequent mitotic spindle malformation[7], This cell
division failure can lead to either aneuploidy or poly-
ploidy, which could in turn contribute to the higher inci-
dence of tumors in heterozygous mice. As an initial step
in further characterizing the effect of lower Plk4 levels on
the cell, we utilized microarrays to provide a general sur-
vey of differences in the transcript profiles of Plk4 wild-
type and heterozygous MEFs. Here, we report on a spec-
trum of genes that are upregulated or downregulated in
the Plk4 heterozygous MEFs, including the key cell cycle
regulators p53, p21 and chk2 and the presence of
increased p53 levels/activity as a result of Plk4 haploinsuf-
ficiency.
Methods
Establishment of primary mouse embryonic fibroblasts 
(MEFs)
Mouse embryonic fibroblast cell lines were established
from 12.5 day old wild-type and heterozygous Plk4
embryos as previously described [9]. All experiments uti-
lizing mice as well as embryos and cell lines derived from
them were performed in accordance to CCAC guidelines
and approved by the University of Windsor Animal Care
Committee. The MEFs were cultured in Dulbecco's Modi-
fied Eagles Medium (Sigma) containing 20% fetal bovine
serum (Sigma), 1% penicillin-streptomycin (Gibco) and
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250 ug/ml gentamicin (Gibco) and maintained at 37°C
with 5% CO2. All experiments were performed with MEFs
at passage 2–3.
Flow cytometry
Wild type and heterozygous mouse embryonic fibroblasts
were grown to approximately 80% confluency. The MEFs
were then harvested, fixed in 80% ice-cold ethanol,
stained with PI and the cell cycle profiles were determined
by flow cytometry on a Beckman Coulter Cytomics FC
500 flow cytometer. Flow cytometry results were analyzed
using Cytomics RXP Analysis software (Beckman Coul-
ter). Presented results are based on three independent
experiments.
Microarray analysis
MEF cells were grown asynchronously to a confluency of
70–80% with total RNA isolation performed using the
RNeasy Mini Kit (Qiagen). In order to confirm the integ-
rity and quality of the RNA, the RNA was run on the 2100
Bioanalyzer (Agilent) using the RNA 6000 Nano Assay
Kit. Total RNA extracted from MEFs was subjected to
microarray analysis at the University Health Network
(UHN) Microarray Centre in Toronto. The samples were
labeled using the UHN's standard indirect labeling proto-
col and hybridized to a Mouse 22.4K chip. Results are
based on three independent replicates with subsequent
analysis performed using "The Institute for Genomic
Research (TIGR) microarray software suite".
Semi-quantitative RT-PCR
Reverse transcription (RT) was performed using Super-
script II Reverse Transcriptase (Invitrogen) as per the man-
ufacturer's instructions. All forward and reverse primers
for PCR were designed to span intron/exon boundaries in
order to prevent amplification of contaminating genomic
DNA in the cDNA mixture. Primers for the amplification
of Plk4, glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), Prohibitin, Sap30 Binding Protein (SAP30BP),
and Wnt-Inducible Signaling Pathway Protein (WISP1)
and the size of their respective products are summarized
in Table 1. PCR was performed using Hot Start Taq DNA
Polymerase (Qiagen) and the results of each amplification
were normalized to the GAPDH internal control.
Exposure of MEFs to DNA damaging agents
Wild-type and heterozygous MEFs were exposed to ultra-
violet light (UV) at 40 mJ/cm2 using a GS Gene Linker UV
Chamber (Biorad) or ionizing radiation (IR) of 25 Gy
using a RX-650 Cabinet X-ray System (Faxitron) and RNA
or protein was isolated from the MEFs at the specified
time points.
Western blot analysis
Cells were lysed in lysis buffer (50 mM Tris-Cl, 100 mM
Nacl, 500 mM EDTA, 1% Triton-X), the cell lysate was
cleared by centrifugation and equal amount of total pro-
tein was loaded into 8% (or 12%) SDS-PAGE gels. Follow-
ing separation, proteins were transferred onto a PVDF
membrane, and Western blot analysis was performed
using standard methods. The primary antibodies were as
follows, anti-p53 (Sigma), anti-Chk2 (Sigma), anti-Chk1,
(Sigma), anti-p21 (BD Pharmingen), anti-Cdc25C (Santa
Cruz) and anti-GAPDH (Cell Signalling). The secondary
antibodies were as follow: anti-mouse HRP (Amersham),
anti-rabbit HRP (Amersham) and were used at dilutions
recommended by manufacturers.
Apoptosis assay
The level of apoptosis was determined in heterozygous
and wild-type Plk4 MEFs using a TdT-mediated dUTP
Nick-End Labeling (TUNEL) assay as per the manufac-
turer's provided protocol (Promega). Cells were exposed
to 40 mJ/cm2 to induce UV mediated DNA damage and
analyzed 1 hr, 2 hr, 4 hr, 6 hr, and 8 hr post radiation.
Results are based on three independent experiments.
Table 1: Oligonucleotide primer sequences for RT-PCR analysis.
Gene Primers Size (bp)
GAPDH Forward 5'GCTGAGTATGTCGTGGAGTCT-3'
Reverse 5'-CAGAGCTGAACGGGAAGCTC-3'
410
Plk4 Forward 5'-AGGGAAGCTAGGCACTTCATG-3'
Reverse 5'-GGAAGACCACCTTTTGAC-3'
310
Sap30 Forward 5'-CCAGAAGCTCTACGAGCGGAA-3'
Reverse 5'TGGTCTGAAGACTCCTACTATGAG-3'
190
Prohibitin Forward 5'-CGTATCTACACCAGCATTGGC-3'
Reverse 5'-TGTGGTGGAAAAGGCTGAGC-3'
301
Wisp1 Forward 5'-GCCTAATCACAGATGGCTGTG-3;
Reverse 5'-CAATAGGAGTGTGTGCACAGGTG-3'
150
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X-gal senescence staining
MEFs were grown to 70–80% confluency and then stained
using a β-Galactosidase Staining Kit (Cell Signalling).
Cells were washed in PBS, fixed in a 2% formaldehyde
solution and incubated overnight in 20 mg/ml X-gal
staining solution. Senescent cells were identified by the
presence of a typical perinuclear blue stain.
p53 activity assay
The activity of p53 from Plk4 heterozygous and wild-type
MEFs was analyzed with the Active p53 Activity Assay Kit
(R*#38;D Systems). Cells were grown to 70–80% conflu-
ency and 5 ug of nuclear extracts (equal amounts of pro-
tein were determined by Bradford assay, Biorad) were
subjected to the capture ELISA assay as per the manufac-
turer's protocol. Absorbance measurements were per-
formed at 450 nm on a Victor 1420 Spectrophotometer.
Results are based on three independent experiments and
normalized to the wild-type controls.
Results and discussion
Comparison between transcript profiles in wild-type and 
heterozygous Plk4 MEFs using microarray
A number of phenotypic differences have been observed
between wild-type and heterozygous Plk4 MEFs [10]. For
example, heterozygous MEFs exhibit a growth rate
approaching one half that of their wild-type counterparts
[10]. Many of these cells contain multiple centrosomes,
micronuclei and mitotic defects [10]. In the present study
we examined the cell cycle profiles of Plk4 heterozygous
MEFs in comparison to wild-type MEFs and found that
the heterozygous MEFS displayed a decrease in cells in
G0/G1 and an increase in the number of cells in G2/M
(Figure 1). These results suggest that Plk4 haploinsuffi-
ciency may also lead to impaired progression through the
cell cycle with the potential to lead to abnormal chromo-
somal alignment and segregation. Plk4 haploinsufficiency
and loss of heterozygosity have also been implicated in
the development of primary hepatocellular carcinoma in
mice and humans respectively [10].
The main focus of the present study was to examine global
changes in transcript profiles between Plk4 wild type and
heterozygous MEFs. In order to accomplish this, we uti-
lized independent cultures of asynchronously growing
age matched Plk4 wild-type and heterozygous MEFs in
three replicates. Quantification and normalization of the
data was performed using "The Institute for Genomic
Research" (TIGR) TM4 microarray data analysis suite.
Normalization and filtering of the data was performed
using the TIGR Microarray Data Analysis System (MIDAS)
application. Analysis of all microarray data sets for the dif-
ferent microarray experiments (ex. Wild-type Plk4 MEFs vs
Heterozygous Plk4 MEFs) were performed independently.
K-means clustering analysis was performed using TIGR
Multiexperiment Viewer (MEV). Within each cluster,
genes having a log ratio value greater than 1 or less than -
1 on each microarray chip were identified. Genes having a
log ratio greater than 1 represented genes in the hetero-
zygous MEFs that have at least a two fold increase in gene
expression. As the wild-type MEFs was used as the control,
genes with a log ratio greater than 1 were classified as up-
regulated in the heterozygous MEFs and genes with a log
Cell cycle profile of Plk4 heterozygous and wild-type MEFsFigure 1
Cell cycle profile of Plk4 heterozygous and wild-type MEFs. Presented are typical cell cyle profiles of asynchronous 
populations of Plk4 heterozygous and wild-type MEFs based on flow cytometry of propidium iodide stained cells. The data is 
representative of three independent experiments.
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ratio less -1 represented genes in the wild-type MEFs that
have at least a two fold increase in gene expression or are
down-regulated in the heterozygous MEFs.
From the microarray data, 9 genes were identified as hav-
ing at least a two-fold decrease in transcript levels in the
heterozygous MEFs when compared to the wild-type con-
trol (Table 2), while 143 genes were identified as having
at least a two-fold increase in transcript levels in the heter-
ozygous MEFs (Table 2). We ordered these genes within
each functional group based on the average fold differ-
ence between Plk4 wild-type and heterozygous MEFs. In
order to test the validity of the microarray results we
assessed transcript levels for Plk4 and three arbitrary genes
with at least a two-fold increase in expression by qualita-
tive RT-PCR. A graphic representation of these results is
shown in Figure 2A. In confirmation of previously pub-
lished results [10], Plk4 transcripts levels in the hetero-
zygous Plk4 MEFs are at about 60% of the level seen in
wild-type MEFs. Furthermore, Prohibitin, Wisp1 and
Sap30 are upregulated in the Plk4 heterozygous MEFs thus
independently confirming their altered expression profile
as identified by microarray results.
The presumed major cellular function for each down or
up-regulated gene was identified using annotation data
from the PubMed database, and/or the Online Mendelian
Inheritance in Man (OMIM) database. Furthermore, we
utilized GenMAPP 2 [23] and Panther [24] to identify glo-
bal biological trends in our gene expression data. The few
genes that were downregulated in Plk4 heterozygous MEFs
functionally included genes involved in development and
metabolism. Far more genes were upregulated than were
downregulated in the heterozygous MEFs. These included
genes with a spectrum of known functions such as cell
cycle control, the DNA damage response, DNA repair, epi-
genetic modification, development, and transcription/
translation. In particular, several key genes involved in
p53 dependent pathways, Rho signaling, Wnt signaling
and the proteasome were upregulated in the heterozygous
MEFs. Several of these genes have been implicated in
malignancy and are of particular interest given the
increased rate of malignancy previously identified in Plk4
heterozygous mice. This includes securin (Pttg1) which
serves to prevent premature chromosome separation
through inhibition of separase activity. Securin is involved
in several key cellular events including mitosis, cell cycle
progression, DNA repair and apoptosis. Furthermore,
securin (Pttg1) is upregulated in several malignancies and
in particularly, pituitary adenomas [25]. Casein Kinase II
(Csnk2a1), a serine/threonine kinase is a positive regula-
tor of Wnt signalling pathway that is also upregulated in
most cancers [26]. Phosphatidylinositol 3-kinase
(Pic3c2a) is an upstream regulator of Akt [27], both of
which are aberrantly regulated in many cancer types and
as such are prime targets for intervention [28], Wisp1
overexpression has been implicated in cellular morpho-
logical transformation [29] and hepatocellular carcinoma
[30].
The observation that the expression levels of genes
involved in p53 dependent pathways were altered, cou-
pled with the known interaction of p53 with Plk4, and
since changes in p53 levels, like Plk4, may also contribute
to centrosome abnormalities [24,31,32], led us to further
analyze this result. We therefore analyzed the promoter
region of both the up and downregulated genes utilizing
the MAPPER search engine [33,34] and found that the
majority of these genes contained numerous p53 respon-
sive elements within the first 5 kilobases upstream of the
transcriptional start site. Furthermore, several of these
upregulated genes are known p53 targets (including msh2
[35]) or affect the p53 transcriptional machinery (like
CDK8 [36]).
The effect of ionizing and ultraviolet radiation on the Plk4 
transcript and protein profiles in MEFs
The Plks are known components of DNA damage path-
ways, affecting levels and activity of a number of key pro-
teins including p53, Chk2, Cdc25C and others. Plk4 is
known to interact with proteins involved in the response
to DNA damage including p53 [20], Cdc25C [22] and
Chk2 [37]. This characteristic, coupled with the observa-
tion that many of the upregulated genes contain numer-
ous p53 responsive elements within their promoter, led us
to examine the effect of DNA damaging agents on the lev-
els of key genes involved in the DNA damage response in
the context of Plk4 levels. Wild-type and heterozygous
MEFs were exposed to 25 Gy IR or 40 mJ/cm2 UV and
changes in transcript levels were analyzed by semi-quanti-
tative RT-PCR. In response to IR, we found no significant
difference in Plk4 transcript levels between wild-type and
heterozygous MEFs (Figure 2B). In contrast, upon expo-
sure to UV, there is a striking difference in transcript pro-
file levels of Plk4 between Plk4 wild-type and
heterozygous MEFs (Figure 2C). Initially, post exposure to
UV, Plk4 transcripts are undetectable in both wild-type
and heterozygous MEFs. Interestingly two hours post UV
exposure plk4 transcripts levels in the wild-type MEFs
returned to control levels and then subsequently increase
to 40% greater expression, while no Plk4 transcripts are
detectable in the heterozygous MEFs. Unfortunately, we
were unable to detect Plk4 protein in these MEFs with the
commercially available antibodies. As our array results
suggest that p53 activity may be increased in the Plk4 het-
erozygotes, we were therefore interested in examining p53
protein levels. We found a sharp contrast between wild-
type and heterozygous MEFs, with levels of p53 protein
expression substantially higher in the heterozygotes (Fig-
ure 3a). These results would seem to suggest that the levels
of p53 in the heterozygous MEFs may be the result of
DNA damage that occurs as a result of genomic instability.
BMC Genomics 2009, 10:319 http://www.biomedcentral.com/1471-2164/10/319
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Comparison of transcript levels between Plk4 heterozygous and wild-type MEFsFigure 2
Comparison of transcript levels between Plk4 heterozygous and wild-type MEFs. A) Confirmation of microar-
ray results. Semi-quantitative RT-PCR was carried out to measure the relative difference in the expression of Plk4 and the 
candidate genes prohibitin, wisp1 and sap30bp in Plk4 wild-type and heterozygous MEFs. Values in each case were normalized 
to the levels of GAPDH transcript. Presented data are a result of three independent experiments. B) Relative levels of Plk4 
transcript post ionizing radiation (IR). MEFs were exposed to 25 Gy IR and RNA was isolated at the indicated time points 
post exposure followed by RT-PCR to measure the relative abundance of Plk4 transcript (as above). C) Relative levels of 
Plk4 transcript post ultraviolet radiation (UV). MEFs were exposed to 40 J/Cm2 UV and RNA was isolated at the indi-
cated time points post exposure followed by RT-PCR to measure the relative abundance of Plk4 transcript (as above).
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Table 2: Transcripts up and down regulated in Plk4 heterozygous MEFs.
Upregulated Genes
Cell Cycle Gene ID Fold Change Putative p53 site Metabolism Gene ID Fold Change Putative p53 site
Casein kinase II (Csnk2a1) 12995 5.8040 20 N-acylsphingosine 
amidohydrolase (acid 
ceramidase) like (Asahl)
11886 6.0539 14
Protein phosphatase 1F 
(PP2C domain containing) 
(Ppm1f)
68606 4.8644 10 Leucyl/cystinyl 
aminopeptidase (Lnpep)
240028 4.8539 6
Squamous cell carcinoma 
antigen recognized by T-
cells 1 (Sart1)
20227 4.6888 20 Galactose-4-epimerase 
(Gale)
74246 4.7700 8
Origin recognition complex, 
subunit 4-like (Orc4l)
26428 4.5661 9 L-2-hydroxyglutarate 
dehydrogenase (L2hgdh)
217666 4.6257 15
Inhibitor of DNA binding 2 
(Id2)
15902 4.4323 11 Fatty acid desaturase 3 
(Fads3)
286922 4.2976 27
Protein phosphatase 5 
(Ppp5c)
65179 4.0765 15 Carbohydrate 
sulfotransferase 2 (Chst2)
54371 4.2926 18
heme binding protein 2 
(Hebp2)
56016 3.8955 10 Stearoyl-Coenzyme A 
desaturase 1 (Ankrd13c)
433667 3.9806 16
Neuropilin (Nrp1) 18186 3.0956 13 CCR4 carbon catabolite 
repression like 4 (Ccrn4l)
310395 3.7939 14
Prohibitin (Phb) 18673 3.0459 18 protein kinase, cAMP 
dependent regulatory, type I 
beta (Prkar1b)
19085 3.3199 18
Cyclin dependent kinase 8 
(Cdk8)
264064 3.0094 17 DNA Repair
Heterogeneous nuclear 
ribonucleoprotein C 
(Hnrpc)
15381 2.5962 8 Uracil-DNA glycosylase 
(Ung)
22256 4.1846 15
TVMSFG fibroblast growth 
factor receptor 1 precursor 
(Fgfr1)
14182 2.2643 18 MutS homolog 6 (Msh6) 17688 2.1811 23
Phosphatidylinositol 3-
kinase (Pic3c2a)
18704 2.1636 9 Thymine DNA glycosylase 
(Tdg)
21665 2.0156 10
Pituitary tumor-
transforming 1 (Pttg1)
30939 1.9518 11
Development Transcriptional/Translational Regulation
Sal-like 3 (Sall3) 20689 7.9335 13 Cysteinyl-tRNA synthetase 
(Cars)
27267 4.8072 18
T-cell factor 4 (Rab27b) 80718 4.7804 14 Zinc Finger Protein 451 
(Zfp451)
98403 4.1537 9
Nuclear receptor co-
repressor 1 (Ncor1)
20185 4.4658 16 Tetratricopeptide repeat 
domain 1 (Ttc1)
66827 4.0003 20
Inositol 1,4,5-triphosphate 
receptor 5 (Itpr2)
16439 3.6909 10 Highly similar to 
CBP_MOUSE CREB-binding 
protein (Crebbp)
12914 3.7483 9
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Procollagen, type VI, alpha 3 
(Col6a3)
12835 3.5828 15 Zinc finger protein 689 
(Zfp689)
71131 3.4636 17
Fetal Alzheimer antigen 
(Bptf)
207165 3.3594 NA Glutamyl-prolyl-tRNA 
synthetase (Eprs)
107508 3.3065 19
WNT1 inducible signaling 
pathway protein 1 (Wisp1)
22402 3.2886 22 GC-rich sequence DNA-
binding factor homolog 
isoform 1 (C21orf66)
67367 3.0984 N/A
T-box transcription factor 
Tbx15 (Tbx15)
21384 2.9248 13 Phenylalanine-tRNA 
synthetase 2 (Fars2)
69955 3.0678 13
Nuclear factor I/X (Nfix) 18032 2.8883 9 GLIS family zinc finger 3 
(Glis3)
226075 2.6233 10
Thrombospondin 2 (Thbs2) 21826 2.5437 23 Transmembrane and 
tetratricopeptide repeat 
containing 2 (Tmtc2)
278279 2.2096 18
Osteopontin (Spp1) 20750 2.4717 15 Transcription factor A 
(Tfam)
21780 2.0680 14
Fukuyama type congenital 
muscular dystrophy 
homolog (Fktn)
246179 2.2362 9
DNA Methylation Cellular/Ion Transport
SAP30 binding protein 
(Sap30bp)
57230 2.9834 8 Pleckstrin (Plek) 56193 6.0575 11
SET domain ERG-associated 
histone methyltransferase 
(Olfml3)
99543 2.0889 9 Syntaxin 18 (Stx18) 53407 5.0970 18
Calcium binding and coiled 
coil domain 1 (Calcoco1)
67488 5.6489 19 Aquaporin-1 (Aqp1) 11826 4.4128 16
Solute carrier family 6 
(Slc6a6)
21366 4.4110 18
Miscellaneous Cellular Functions Exocyst complex component 
3 (Exoc3)
211446 3.9296 10
Coiled Coil domain 
containing 131 (Ccdc131)
216345 6.4372 11 Protein-coupled receptor 19 
(Gpr19)
14760 3.8281 21
Thyroid hormone receptor 
interactor 11 (Trip11)
109181 5.8691 NA Solute carrier family 39 
(Slc39a10)
227059 3.5028 13
Smg-6 homolog (Smg6) 103677 5.3375 11 Frequenin homolog (Freq) 14299 3.1881 15
Talin 2 (Tln2) 70549 5.2780 N/A Serine Hydrolase like (Serhl) 68607 3.1718 17
Tomoregulin 1 (Tmeff1) 230157 5.1116 7 Solute carrier family 14 
(Slc14a2)
27411 3.0842 14
Channel-interacting PDZ 
domain protein (Inadl)
12695 4.9504 14 Translocator of inner 
mitochondrial membrane 
(Timm17b)
21855 2.7129 19
WD repeat domain 50 
(Utp18)
217109 4.9252 16 Similar to crooked neck 
protein (Ipo7)
233726 2.5873 17
Inositol hexaphosphate 
kinase 1 (Ip6k1)
27399 4.8086 12 Oxysterol binding protein 
like protein 9 (Osbpl9)
100273 2.5501 12
Spetex-2E protein 
(100040875)
4.6574 N/A ATPase, Ca++ transporting, 
plasma membrane 2 (Atp2b2)
11941 2.4328 26
Table 2: Transcripts up and down regulated in Plk4 heterozygous MEFs. (Continued)
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Multiple PDZ domain 
protein (Mpdz)
17475 4.0596 12 Transient receptor potential 
cation channel, subfamily M, 
member 7 (Trpm7) 58800
1.9917 11
Myosin heavy chain 10 
(Myh10)
77579 3.8880 11
CDC42 effector protein 
(Rho GTPase binding) 2 
(Cdc42ep2)
104252 3.5581 23 Downregulated Genes
Zinc finger protein 507 
(Zfp507)
668501 3.4688 N/A Development
aarF domain containing 
kinase 1 (Adck1)
72113 3.4641 9 Procollagen, type III, alpha 1 
(Col3a1)
12825 -4.6364 6
AHNAK nucleoprotein 
(Ahnak)
66395 3.2688 20 Procollagen, type V, alpha 2 
(Col5a2)
12832 -4.1420 12
Ring finger protein 11 
(Arhgdia)
192662 3.1199 25 Oral-facial-digital syndrome 1 
gene homolog (Ofd1)
237222 -3.0782 8
Villin (Vil1) 22349 2.9808 15 Procollagen, type I, alpha 2 
(Col1a2)
12843 -2.9648 12
3-phosphoglycerate 
dehydrogenase (Phgdh)
236539 2.9427 18 Metabolism
Arginine/serine-rich coiled-
coil 1 (Rsrc1)
66880 2.9404 6 Stearoyl-Coenzyme A 
desaturase 2 (Scd2)
20250 -2.4729 10
Olfactory receptor 202 
(Olfr202)
258997 2.9278 7 Mus musculus mVL30-1 
retroelement mRNA 
sequence (mVL30-1)
-2.5566 N/A
Discs, large homolog 5 
(Dlg5)
71228 2.9094 N/A Transmembrane protein 34 
(Tmem184c)
234463 -2.5241 14
2'-phosphodiesterase 
(E430028B21Rik)
2.8426 0 Mus musculus 0 day neonate 
cerebellum cDNA 
(E430024C06Rik)
319443 -2.3000 N/A
HD domain containing 3 
(Hdcc3)
68695 2.7345 14 Hypothetical protein 
LOC639390 (LOC639390)
-2.2121 N/A
Heat shock protein 
1(Heatr1)
217995 2.7243 13
Myotubularin related 
protein 7 (Mtmr7)
54384 2.4370 8
Mitochondrial ribosomal 
protein L50 (Mrpl50)
362517 2.2540 20
Proteasome(macropain)26S 
subunit, non-ATPase 
(Psmd4)
19185 2.2031 11
NICE-5 protein (AA414768) 245350 2.1272 N/A
Shown above are ninety-seven upregulated genes and nine downregulated genes in the heterozygous MEFs. "Fold change" is the change in transcript level in the heterozygous MEFs relative to 
wild-type MEFs as determined by microarray analysis. The "Putative p53 sites" are as determined by MAPPER and is based on the first 5000 nucleotides upstream of the transcriptional start site. 
Please note that forty-six downregulated transcripts and their corresponding gene were omitted from the table as they encode hypothetical proteins or have unknown cellular functions. All the 
microarray data has been deposited into the MIAME database under accession number E-MEXP-2161.
Table 2: Transcripts up and down regulated in Plk4 heterozygous MEFs. (Continued)
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We also examined p53 levels in these cells after exposure
to DNA damaging agents based on the differences found
for Plk4 transcript levels 6 hrs post exposure. In the case of
UV we did not see any additional increase in the level of
p53 protein compared to the Plk4 wild-type and heterozy-
gote controls. In contrast, the levels of p53 in the wild-
type MEFs increased to the heterozygote levels when
exposed to IR. The levels were stabilized at close to maxi-
mal levels for these conditions and increased insignifi-
cantly. Results displayed are the representative data from
three independent experiments. We subsequently exam-
ined the levels of a number of known cell cycle control
and DNA damage response proteins. Chk2, which is
known to aid in the maintenance of sustained G1, G2/M
arrest, and apoptosis by phosphorylating p53 [12,38-41],
was also at much higher levels in the heterozygous MEFs
pretreatment (Figure 3b). Upon exposure to UV or ioniz-
ing radiation the levels of Chk2 were elevated in both
wild-type and heterozygous MEFs. We next examined the
levels of p21, a downstream effector and transcriptional
target of p53 and found that the levels were increased in
Plk4 heterozygote MEFs when compared to wild-type (Fig-
ure 3c). Consistent with this result, in our microarray
data, p21 transcript levels were also upregulated 1.95
times (just below our arbitrarily chosen 2 fold cut-off) in
the Plk4 heterozygous MEFs. Additionally, six hours post
DNA damage we observed a substantial increase in p21
levels in the wild-type MEFs, while there was no further
increase apparent in the heterozygous MEFs post DNA
damage. The observation that p21 protein and transcript
levels were elevated in the heterozygous MEFs again corre-
sponds with the aforementioned increased levels of p53.
Furthermore, it is also consistent with the increased levels
of CDK8 transcripts found in the heterozygous MEFs
(Table 2). CDK8 binding to p53 target genes is known to
correlate positively with transcriptional strength. CDK8 is
recruited to the p21 locus during conditions of strong p21
transcriptional activation [36]. We found minimal differ-
ences in the detectable levels of Cdc25C (Figure 3d) and
Chk1 (Figure 3e) prior to or post treatment.
The effect of UV induced DNA damage on apoptosis and 
cell cycle profiles in Plk4 MEFs
As p53 is a major regulator of apoptosis we were next
interested in determining whether the levels of apoptosis
were higher in the Plk4 heterozygous MEFs. Since we
observed a large decrease in the level of plk4 transcripts in
heterozygous MEFs upon UV exposure and since UV is a
more effective inducer of both p53 activity and apoptosis
than IR [42] we examined the levels of apoptosis after UV
treatment. Interestingly, we found no significant differ-
ence in the levels of apoptosis for wild-type and hetero-
zygous MEFs prior to or post treatment with UV (Figure
4A). While we were surprised that there was no difference
in the level of apoptosis between wild-type and hetero-
zygous MEFs, it is consistent with the elevated level of
Wisp1 mRNA seen in the heterozygous MEFs. Wisp1 is
known to attenuate p53 mediated apoptosis through the
activation of PKB/Akt anti-apoptotic pathways [43]. This
results in the protection of cells from the late stages of p53
mediated apoptosis. Additionally, while the cell cycle pro-
files of wild-type and heterozygous MEFs were different
without treatment, their respective responses to UV irradi-
ation were similar with an overall increase in the Sub G0
population post exposure (Figure 4B).
Senescence and p53 activity in Plk4 MEFs
In most cell types p53 is a potential key regulator of senes-
cence growth arrest, the maintenance of senescence
growth arrest and the initiation of the senescence
response following DNA damage [44]. In order to address
the possibility that elevated p53 levels may be correlated
with a senescent phenotype in the Plk4 heterozygous
MEFs, we stained the cells for β-galactosidase activity from
passages 2–5 (see additional file 1). We found no evi-
dence of increased β-galactosidase activity in the Plk4 het-
Comparison of protein levels upon DNA damage between heterozyg us and wild-typ  MEFsFigure 3
Comparison of protein levels upon DNA damage 
between heterozygous and wild-type MEFs. Hetero-
zygous and wild-type Plk4 MEFs were exposed to 25 Gy IR or 
40 mJ/cm2 UV. Six hours post exposure cell extracts were 
subjected to Western Blot analysis. Shown are representa-
tive data from 3 repeats. GAPDH was used as a loading con-
trol to ensure equal protein loading.
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erzoygous MEFs relative to the wild type MEFs; thus
suggesting that the elevated p53 protein levels in the Plk4
heterozygous MEFs were not correlated with an increase
in cellular senescence.
p53 accumulation and activity is regulated by post-trans-
lational modification of at least 20 sites via protein phos-
phorylation and/or other post-translational
modifications [42]. As previously stated, the p53 protein
levels are markedly increased in the Plk4 heterozygous
MEFs compared to wild-type. It was therefore of interest to
determine whether the increase in p53 levels was also
accompanied by an increase in p53 activity. In order test
this possibility we utilized an enzyme-linked immuno-
Assessment of levels of apoptosis and cell cycle arrest in heterozygous and wild-type Plk4 MEFsFigure 4
Assessment of levels of apoptosis and cell cycle arrest in heterozygous and wild-type Plk4 MEFs. A.) Levels of 
apoptosis after UV induced DNA damage in Plk4 heterozygous and wild-type MEFs. Apoptosis was analyzed prior 
to and after UV induced DNA damage (40 mJ/cm2) with a TUNEL assay. The results are presented as a percentage of apoptosis 
positive cells and are representative of three independent experiments. B.) Effect of UV induced DNA damage in Plk4 
heterozygous and wild-type MEFs on progression through the cell cycle. Cell cycle profiles were analyzed prior to 
and after UV induced DNA damage (40 mJ/cm2) by flow cytometry after staining of the DNA with propidium iodide. The pop-
ulation of cells in G0/G1, S, G2/M and Sub G0 are displayed as percentage and are representative of three independent experi-
ments.
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sorbent assay (ELISA) to measure p53 transcriptional
activity in our Plk4 wild-type and heterozygous MEFS.
Interestingly, in agreement with the presence of p53
responsive elements in the genes that were upregulated in
the array data, we observed a 5 fold increase in p53 activ-
ity in the heterozygous MEFs (Figure 5A).
We propose that the increased p53 protein levels and
activity that occur as a result of Plk4 haploinsufficiency
may in turn contribute to the over-expression of numer-
ous genes containing p53 responsive elements within
their promoters (Figure 5B). The function of these genes
encompasses a spectrum of cellular activities including
p53 activity and model of Plk4 and p53 interactions in Plk4 heterozygous MEFsFigure 5
p53 activity and model of Plk4 and p53 interactions in Plk4 heterozygous MEFs. A.) Effect of Plk4 haploinsuffi-
ciency on p53 activity. p53 transcriptional activity was analyzed in Plk4 heterozygous and wild-type MEFs from nuclear 
extracts using a capture ELISA assay. The p53 specificity was confirmed upon incubation with competing labeled and unlabeled 
oligonucleotides. The results were normalized against wild-type control and are representative of three independent experi-
ments. B.) Model of p53 and Plk4 regulation in Plk4 heterozygous and wild-type MEFs. Shown are proposed Plk4/
p53 direct/indirect interactions in Plk4 wild-type and heterozygous MEFs with the resultant corresponding changes in protein 
levels, activity and gene expression. Solid lines indicate pathways that are functionally active, whereas dotted lines indicate path-
ways with reduced activity.
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cell cycle control and the response to DNA damage. The
results suggest that one function of Plk4 phosphorylation
of p53 may be with respect to p53 protein stability and/or
activity. In this scenario the possibility exists that this
arises through a direct effect in which lower Plk4 levels
result in reduced phosphorylation of p53 by Plk4 thus
leading to an increase in protein p53 stability and activity.
Alternatively, the presence of supernumerary centrosomes
seen in Plk4 heterozygous MEFs may lead to an increase in
genomic instability and the induction of checkpoints to
deal with the ensuing DNA damage. Very few targets for
Plk4 have been identified thus far. However, the possibil-
ity exists that the increased levels of p53 and phenotypic
changes observed occur as a result of indirect conse-
quences of Plk4 haploinsufficiency and targeting of other
substrates. For example, one known plausible indirect
effect of Plk4 haploinsufficiency could be through Chk2.
Plk4 both interacts with and phosphorylates Chk2, a key
regulator of the DNA damage response and p53 [37].
Conceivably, reduced phosphorylation of Chk2 as a result
of lower Plk4 levels may result in altered Chk2 levels and/
or activity towards p53 thus resulting in p53's increased
stability or activity. This is consistent with the observation
that Chk2 levels are greatly increased in the heterozygous
MEFs and the observation that the cell cycle profiles of
heterozygous MEFs are altered.
Conclusion
In conclusion, our results demonstrate that Plk4 haploin-
sufficiency leads to changes in the levels of RNA accumu-
lation for a number of key cellular genes as well as changes
in protein levels for several important cell cycle/DNA
damage proteins. The majority of the upregulated genes
have numerous p53 responsive elements within their pro-
moter regions, thus suggesting that Plk4 haploinsufi-
ciency directly or indirectly leads to an increase in p53
activity in MEFs. Further studies should reveal the nature
of the relationship between Plk4 levels, p53 and the down
and upregulated genes found in Plk4 heterozygous MEFs.
Abbreviations
Cdc25C: Cell division cycle 25 homolog C; CDK8: Cyclin
dependent kinase 8; Csnk2a1: Casein Kinase II; GAPDH:
glyceraldehyde 3-phosphate dehydrogenase; HDAC: His-
tone deacetylase; LOH: Loss of heterozygosity; MEFs:
Mouse embryonic fibroblasts; MEV: Multiexperiment
viewer; MIDAS: Microarray Analysis System; OMIM:
Online Mendelian Inheritance in Man; Pic3c2a: Phos-
phatidylinositol 3-kinase; Plk: Polo-like kinase; Plk4:
Polo-like Kinase 4; RT-PCR: reverse trancription polymer-
ase chain reaction; Sak-Snk/Plk-akin kinase; SAP30BP:
Sap 30 binding protein; Sart1: Squamous cell carcinoma
antigen recognized by T-cells; TIGR: The Institute for
Genomic Research; TUNEL: TdT mediated dUTP Nick-
End Labeling; UHN: University Health Network; UV:
Ultraviolet; WISP1: Wnt Inducible Signaling Pathway pro-
tein.
Authors' contributions
AM carried out the initial isolation of MEFs, along with
the RNA isolation, RT-PCR, microarray data analysis and
Western blot analysis of proteins of interest. AW isolated
additional MEFs, performed the flow cytometry analysis,
β-galactosidase assays, and the p53 activity assay. JN per-
formed the analysis and determination of p53 responsive
elements in all genes that were found to be up- or down-
regulated in Plk4 heterozygous MEFs. JWH was involved
in all aspects of the study including conception, design,
and coordination of the study, along with drafting the
manuscript. All authors were involved in reading and
approving the final draft.
Additional material
Acknowledgements
This work is supported by operating grants to JWH from NSERC and 
NCIC (Terry Fox Foundation) as well as research equipment grants to 
JWH from CFI, OIT, NSERC, and NCIC. JN is a recipient of an NSERC 
undergraduate scholarship. The authors wish to thank A. Swan, B. Crosby 
and A. Kozarova for helpful suggestions.
References
1. Sunkel CE, Glover DM: polo, a mitotic mutant of Drosophila
displaying abnormal spindle poles.  J Cell Sci 1988, 89(Pt
1):25-38.
2. Glover DM, Hagan IM, Tavares AA: Polo-like kinases: a team that
plays throughout mitosis.  Genes Dev 1998, 12(24):3777-3787.
3. Toczyski DP, Galgoczy DJ, Hartwell LH: CDC5 and CKII control
adaptation to the yeast DNA damage checkpoint.  Cell 1997,
90(6):1097-1106.
4. Sanchez Y, Bachant J, Wang H, Hu F, Liu D, Tetzlaff M, Elledge SJ:
Control of the DNA damage checkpoint by chk1 and rad53
protein kinases through distinct mechanisms.  Science 1999,
286(5442):1166-1171.
5. Nigg EA: Centrosome duplication: of rules and licenses.  Trends
Cell Biol 2007, 17(5):215-221.
6. Bettencourt-Dias M, Rodrigues-Martins A, Carpenter L, Riparbelli M,
Lehmann L, Gatt MK, Carmo N, Balloux F, Callaini G, Glover DM:
SAK/PLK4 is required for centriole duplication and flagella
development.  Curr Biol 2005, 15(24):2199-2207.
7. Habedanck R, Stierhof YD, Wilkinson CJ, Nigg EA: The Polo kinase
Plk4 functions in centriole duplication.  Nat Cell Biol 2005,
7(11):1140-1146.
Additional file 1
Supplementary Figure 1. Figure showing the results from the X-gal assay 
in plk4 wild type and heterozygous MEFs. Differences in senescence were 
determined at passages 3–5 for heterozygous and wild-type Plk4 MEFs by 
β-galactosidase assay. Senescing Human foreskin fibroblast (HFF-1) 
(passage 52) were used as a positive control. Arrows point to the charac-
teristic blue perinuclear staining.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-10-319-S1.ppt]
Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Genomics 2009, 10:319 http://www.biomedcentral.com/1471-2164/10/319
Page 14 of 14
(page number not for citation purposes)
8. Kleylein-Sohn J, Westendorf J, Le Clech M, Habedanck R, Stierhof YD,
Nigg EA: Plk4-induced centriole biogenesis in human cells.
Dev Cell 2007, 13(2):190-202.
9. Hudson JW, Kozarova A, Cheung P, Macmillan JC, Swallow CJ, Cross
JC, Dennis JW: Late mitotic failure in mice lacking Sak, a polo-
like kinase.  Curr Biol 2001, 11(6):441-446.
10. Ko MA, Rosario CO, Hudson JW, Kulkarni S, Pollett A, Dennis JW,
Swallow CJ: Plk4 haplo-insufficiency causes mitotic infidelity
and carcinogenesis.  Nature Genetics 2005, 37:883-888.
11. Ouyang B, Li W, Pan H, Meadows J, Hoffmann I, Dai W: The physi-
cal association and phosphorylation of Cdc25C protein phos-
phatase by Prk.  Oncogene 1999, 18(44):6029-6036.
12. Matsuoka S, Huang M, Elledge SJ: Linkage of ATM to cell cycle
regulation by the Chk2 protein kinase.  Science 1998,
282(5395):1893-1897.
13. Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS, Piwnica-Worms H:
Mitotic and G2 checkpoint control: regulation of 14-3-3 pro-
tein binding by phosphorylation of Cdc25C on serine-216.
Science 1997, 277(5331):1501-1505.
14. Toyoshima-Morimoto F, Taniguchi E, Nishida E: Plk1 promotes
nuclear translocation of human Cdc25C during prophase.
EMBO Rep 2002, 3(4):341-348.
15. Ando K, Ozaki T, Yamamoto H, Furuya K, Hosoda M, Hayashi S,
Fukuzawa M, Nakagawara A: Polo-like kinase 1 (Plk1) inhibits
p53 function by physical interaction and phosphorylation.  J
Biol Chem 2004, 279(24):25549-25561.
16. Xie S, Wu H, Wang Q, Cogswell JP, Husain I, Conn C, Stambrook P,
Jhanwar-Uniyal M, Dai W: Plk3 functionally links DNA damage
to cell cycle arrest and apoptosis at least in part via the p53
pathway.  J Biol Chem 2001, 276(46):43305-43312.
17. Tsvetkov LM, Tsekova RT, Xu X, Stern DF: The Plk1 Polo box
domain mediates a cell cycle and DNA damage regulated
interaction with Chk2.  Cell Cycle 2005, 4(4):609-617.
18. Bahassi el M: Mammalian Polo-like kinase 3 (Plk3) is a multi-
functional protein involved in stress response pathways.
Nature Structural Biology 2002, 9(10):719-724.
19. Bahassi el M, Myer DL, McKenney RJ, Hennigan RF, Stambrook PJ:
Priming phosphorylation of Chk2 by polo-like kinase 3 (Plk3)
mediates its full activation by ATM and a downstream check-
point in response to DNA damage.  Mutat Res 2006, 596(1–
2):166-176.
20. Swallow CJ, Ko MA, Siddiqui NU, Hudson JW, Dennis JW: Sak/Plk4
and Mitotic Fidelity.  Oncogene 2005, 24(2):306-312.
21. Li J, Tan M, Li L, Pamarthy D, Lawrence TS, Sun Y: SAK, a new polo-
like kinase, is transcriptionally repressed by p53 and induces
apoptosis upon RNAi silencing.  Neoplasia 2005, 7(4):312-323.
22. Bonni S, Ganuelas ML, Petrinac S, Hudson JW: Human Plk4 phos-
phorylates Cdc25C.  Cell Cycle 2008, 7(4):545-547.
23. Dahlquist KD, Salomonis N, Vranizan K, Lawlor SC, Conklin BR:
GenMAPP, a new tool for viewing and analyzing microarray
data on biological pathways.  Nat Genet 2002, 31(1):19-20.
24. Thomas PD, Kejariwal A, Campbell MJ, Mi H, Diemer K, Guo N,
Ladunga I, Ulitsky-Lazareva B, Muruganujan A, Rabkin S, et al.: PAN-
THER: a browsable database of gene products organized by
biological function, using curated protein family and sub-
family classification.  Nucleic Acids Res 2003, 31(1):334-341.
25. Tfelt-Hansen J, Kanuparthi D, Chattopadhyay N: The emerging
role of pituitary tumor transforming gene in tumorigenesis.
Clin Med Res 2006, 4(2):130-137.
26. Seldin DC, Landesman-Bollag E, Farago M, Currier N, Lou D,
Dominguez I: CK2 as a positive regulator of Wnt signalling and
tumourigenesis.  Mol Cell Biochem 2005, 274(1–2):63-67.
27. Nicholson KM, Anderson NG: The protein kinase B/Akt signal-
ling pathway in human malignancy.  Cell Signal 2002,
14(5):381-395.
28. Yuan TL, Cantley LC: PI3K pathway alterations in cancer: vari-
ations on a theme.  Oncogene 2008, 27(41):5497-5510.
29. Xu L, Corcoran RB, Welsh JW, Pennica D, Levine AJ: WISP-1 is a
Wnt-1- and beta-catenin-responsive oncogene.  Genes Dev
2000, 14(5):585-595.
30. Cervello M, Giannitrapani L, Labbozzetta M, Notarbartolo M, D'Ales-
sandro N, Lampiasi N, Azzolina A, Montalto G: Expression of
WISPs and of their novel alternative variants in human hepa-
tocellular carcinoma cells.  Ann N Y Acad Sci 2004, 1028:432-439.
31. Fukasawa K: Centrosome amplification, chromosome instabil-
ity and cancer development.  Cancer Lett 2005, 230(1):6-19.
32. Shinmura K, Bennett RA, Tarapore P, Fukasawa K: Direct evidence
for the role of centrosomally localized p53 in the regulation
of centrosome duplication.  Oncogene 2007, 26(20):2939-2944.
33. Marinescu VD, Kohane IS, Riva A: The MAPPER database: a
multi-genome catalog of putative transcription factor bind-
ing sites.  Nucleic Acids Res 2005:D91-97.
34. Marinescu VD, Kohane IS, Riva A: MAPPER: a search engine for
the computational identification of putative transcription
factor binding sites in multiple genomes.  BMC Bioinformatics
2005, 6:79.
35. Warnick CT, Dabbas B, Ford CD, Strait KA: Identification of a p53
response element in the promoter region of the hMSH2
gene required for expression in A2780 ovarian cancer cells.
J Biol Chem 2001, 276(29):27363-27370.
36. Donner AJ, Szostek S, Hoover JM, Espinosa JM: CDK8 is a stimulus-
specific positive coregulator of p53 target genes.  Mol Cell
2007, 27(1):121-133.
37. Petrinac S, Ganuelas ML, Bonni S, Nantais J, Hudson JW: Polo-like
kinase 4 phosphorylates Chk2.  Cell Cycle 2009, 8(2):327-329.
38. Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K, Elledge SJ:
Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo
and in vitro.  Proc Natl Acad Sci USA 2000, 97(19):10389-10394.
39. Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H, Liu
D, Elledge SJ, Mak TW: DNA damage-induced activation of p53
by the checkpoint kinase Chk2.  Science 2000,
287(5459):1824-1827.
40. Chehab NH, Malikzay A, Appel M, Halazonetis TD: Chk2/hCds1
functions as a DNA damage checkpoint in G(1) by stabilizing
p53.  Genes Dev 2000, 14(3):278-288.
41. Shieh SY, Ahn J, Tamai K, Taya Y, Prives C: The human homologs
of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate
p53 at multiple DNA damage-inducible sites.  Genes Dev 2000,
14(3):289-300.
42. Saito S, Yamaguchi H, Higashimoto Y, Chao C, Xu Y, Fornace AJ Jr,
Appella E, Anderson CW: Phosphorylation site interdepend-
ence of human p53 post-translational modifications in
response to stress.  J Biol Chem 2003, 278(39):37536-37544.
43. Su F, Overholtzer M, Besser D, Levine AJ: WISP-1 attenuates p53-
mediated apoptosis in response to DNA damage through
activation of the Akt kinase.  Genes Dev 2002, 16(1):46-57.
44. Beausejour CM, Krtolica A, Galimi F, Narita M, Lowe SW, Yaswen P,
Campisi J: Reversal of human cellular senescence: roles of the
p53 and p16 pathways.  EMBO J 2003, 22(16):4212-4222.
